Study for Patients With Non Small Cell Lung Cancer (NSCLC)
This is a randomized study to assess the efficacy and safety of chemotherapy with platin compared to chemotherapy without platin.
Carcinoma, Non-Small-Cell Lung
DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Vinorelbine
Determination of response rate (stable disease [SD] or better)|Determination of safety of the combination and life quality
Determination of remission rate|Determination of time to progression|Determination of 1-year survival rate
Randomized Phase II design, multicenter study, to assess the efficacy and safety of combined chemotherapy with Paclitaxel and Carboplatin versus a platinum free chemotherapy with Paclitaxel and Vinorelbine, within the combination therapies there are two different dosing intervals, which will be assessed as well (4 Arm study).